Literature DB >> 26789720

Severe Short Stature in Two Siblings as the Presenting Sign of ACP5 Deficiency.

Christiaan de Bruin1, Zerrin Orbak, Melissa Andrew, Vivian Hwa, Andrew Dauber.   

Abstract

BACKGROUND: ACP5 deficiency is known to cause spondyloenchondrodysplasia (SPENCD), which is characterized by various autoimmune and neurological symptoms in addition to short stature.
METHODS: Two siblings from a consanguineous Turkish family, a girl aged 13 years (P1) and a boy aged 8 years (P2), presented to their endocrinologist with progressive growth failure and severe short stature (-5 SDS). They had no comorbid conditions and, on physical examination, there were no signs of an overt skeletal dysplasia with normal appearance of extremities. Other than a low baseline IGF-1, extensive laboratory workup, including growth hormone stimulation and IGF-1 generation tests, was normal. Exome sequencing was performed.
RESULTS: Exome sequencing identified the presence of a homozygous frameshift mutation (p.Ser258Trpfs*39) in ACP5 in both siblings, which was confirmed by Sanger sequencing. This specific mutation has previously been described in patients with SPENCD. Additional workup in the two siblings showed distinct features of skeletal dysplasia on X-rays consistent with SPENCD, but none of the common autoimmune or neurological abnormalities associated with this condition.
CONCLUSION: Severe short stature can be the only presenting sign of ACP5 deficiency and the latter could therefore be considered as a rare cause in the differential diagnosis of severe, proportionate growth failure.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26789720      PMCID: PMC4891295          DOI: 10.1159/000443684

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  11 in total

1.  Sitting height and sitting height/height ratio references for Turkish children.

Authors:  Rüveyde Bundak; Firdevs Bas; Andrzej Furman; Hülya Günöz; Feyza Darendeliler; Nurçin Saka; Sükran Poyrazoğlu; Olcay Neyzi
Journal:  Eur J Pediatr       Date:  2014-01-09       Impact factor: 3.183

2.  Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disordered macrophage inflammatory responses and reduced clearance of the pathogen, Staphylococcus aureus.

Authors:  A J Bune; A R Hayman; M J Evans; T M Cox
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

3.  An XRCC4 splice mutation associated with severe short stature, gonadal failure, and early-onset metabolic syndrome.

Authors:  Christiaan de Bruin; Verónica Mericq; Shayne F Andrew; Hermine A van Duyvenvoorde; Nicole S Verkaik; Monique Losekoot; Aleksey Porollo; Hernán Garcia; Yi Kuang; Dan Hanson; Peter Clayton; Dik C van Gent; Jan M Wit; Vivian Hwa; Andrew Dauber
Journal:  J Clin Endocrinol Metab       Date:  2015-03-05       Impact factor: 5.958

4.  Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity.

Authors:  Ekkehart Lausch; Andreas Janecke; Matthias Bros; Stefanie Trojandt; Yasemin Alanay; Corinne De Laet; Christian A Hübner; Peter Meinecke; Gen Nishimura; Mari Matsuo; Yoshiko Hirano; Sylvie Tenoutasse; Andrea Kiss; Rafael Fabiano Machado Rosa; Sharon L Unger; Raffaele Renella; Luisa Bonafé; Jürgen Spranger; Sheila Unger; Bernhard Zabel; Andrea Superti-Furga
Journal:  Nat Genet       Date:  2011-01-09       Impact factor: 38.330

5.  Spondyloenchondrodysplasia. Enchondromatomosis with severe platyspondyly in two brothers.

Authors:  S Schorr; C Legum; M Ochshorn
Journal:  Radiology       Date:  1976-01       Impact factor: 11.105

6.  Two further cases of spondyloenchondrodysplasia (SPENCD) with immune dysregulation.

Authors:  V Navarro; C Scott; T A Briggs; S Barete; C Frances; P Lebon; T Maisonobe; G I Rice; C H Wouters; Y J Crow
Journal:  Am J Med Genet A       Date:  2008-11-01       Impact factor: 2.802

7.  Spondyloenchondrodysplasia with spasticity, cerebral calcifications, and immune dysregulation: clinical and radiographic delineation of a pleiotropic disorder.

Authors:  Raffaele Renella; Elke Schaefer; Martine LeMerrer; Yasemin Alanay; Nurgun Kandemir; Georg Eich; Teresa Costa; Diana Ballhausen; Eugen Boltshauser; Luisa Bonafé; Andres Giedion; Sheila Unger; Andrea Superti-Furga
Journal:  Am J Med Genet A       Date:  2006-03-15       Impact factor: 2.802

8.  Whole exome sequencing to identify genetic causes of short stature.

Authors:  Michael H Guo; Yiping Shen; Emily C Walvoord; Timothy C Miller; Jennifer E Moon; Joel N Hirschhorn; Andrew Dauber
Journal:  Horm Res Paediatr       Date:  2014-06-20       Impact factor: 2.852

9.  Unexpected high frequency of skeletal dysplasia in idiopathic short stature and small for gestational age patients.

Authors:  I Flechtner; K Lambot-Juhan; R Teissier; A Colmenares; G Baujat; J Beltrand; Z Ajaltouni; C Pauwels; G Pinto; D Samara-Boustani; A Simon; C Thalassinos; M Le Merrer; V Cormier-Daire; M Polak
Journal:  Eur J Endocrinol       Date:  2014-04-10       Impact factor: 6.664

10.  Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis.

Authors:  A R Hayman; S J Jones; A Boyde; D Foster; W H Colledge; M B Carlton; M J Evans; T M Cox
Journal:  Development       Date:  1996-10       Impact factor: 6.868

View more
  2 in total

1.  A Case with Spondyloenchondrodysplasia Treated with Growth Hormone.

Authors:  Takanori Utsumi; Satoshi Okada; Kazushi Izawa; Yoshitaka Honda; Gen Nishimura; Ryuta Nishikomori; Rika Okano; Masao Kobayashi
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-10       Impact factor: 5.555

2.  Characterisation of ACP5 missense mutations encoding tartrate-resistant acid phosphatase associated with spondyloenchondrodysplasia.

Authors:  Janani Ramesh; Latha K Parthasarathy; Anthony J Janckila; Farhana Begum; Ramya Murugan; Balakumar P S S Murthy; Rif S El-Mallakh; Ranga N Parthasarathy; Bhuvarahamurthy Venugopal
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.